Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

29 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Metabolism in the Lymphatic Niche of CLL

NCT05610228

CLL

UNKNOWN

Heavy Light Chain in Chronic Lymphocytic Leukemia

NCT02377869

CLL

UNKNOWN

B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging

NCT01028430

Chronic Lymphocytic Leukemia

COMPLETED

Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

NCT01380587

Acute Lymphoblastic Leukemia

COMPLETED

C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia

NCT03150849

Chronic Lymphocytic Leukemia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL expression correlates with a more aggressive type of CLL. The investigators propose that LPL protein expression on CLL cells is prognostic and that LPL and other proteins involved in fatty acid metabolism are critical for CLL cells to survive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No treatment

No intervention. Each patient will have blood drawn at a standard of care venipuncture.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
* Patients undergoing routine blood draws as part of their ongoing follow up for CLL
* 18 years or older
* Ability to provide consent in English
* Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.

Exclusion Criteria

* Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
* other hematologic malignancy or other disease process within the past 6 months are excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No